V

Vaxcyte

Develops broad-spectrum vaccines for bacterial infections

Executive Director - Digital Enablement

Full-Time
$288k - $335k+ Equity component
Expert
Bachelor's, Master's, MBA
Remote in USA
RemoteRelocation assistance is available; travel is required 20% of the time.
ProductProduct Management

About the job

Requirements
  • A BA/BS degree in a scientific discipline, business, marketing, or technology is required; an MBA or other advanced degree is highly desired. Other combinations of education and/or experience may be considered.
  • At least 16 years of industry-related experience, including at least 5 years in commercial or commercial-facing roles within pharmaceutical, biotech, or vaccine organizations and direct exposure to product launch.
  • Experience operating with product management discipline, including owning a product roadmap, managing a backlog, working in iterative delivery cycles, and measuring outcomes.
  • Experience building or leading a commercial digital or commercial excellence function, with accountability for adoption and business results, not just technical delivery.
  • Deep understanding of the commercial technology ecosystem, including customer relationship management systems such as Salesforce or Veeva, marketing automation platforms, data and analytics platforms, and healthcare professional-facing digital channels.
  • Deep understanding of frontier AI models and their applications in business.
  • Ability to translate commercial strategy into technical requirements and technical constraints into business options.
  • Working knowledge of generative AI, predictive analytics, next-best-action tools, and AI-assisted content workflows.
  • Familiarity with revenue management infrastructure, including chargebacks, rebates, and gross-to-net systems.
  • Familiarity with Sunshine Act compliance, MLR review workflows, and promotional materials management.
  • Ability to travel 20% of the time for commercial and cross-functional team engagements.
Responsibilities
  • Develop a phased commercial digital vision for the U.S. adult launch covering pre-launch, launch, and growth phases, with defined milestones and measurable outcomes at each stage.
  • Own and maintain a commercial product roadmap that treats each digital capability—including customer relationship management, marketing technology, field enablement, analytics, and AI tools—as a discrete product with a use case, user, success metric, and release schedule.
  • Map the end-to-end commercial experience from account manager and field representative perspectives through provider and executive touchpoints, identifying where digital creates leverage and where added complexity should be avoided.
  • Define and prioritize AI use cases for field force effectiveness, marketing operations, customer segmentation, content production, and performance analytics, sequencing them by business impact and data readiness.
  • Ensure technology decisions follow a defined commercial use case, with architecture following strategy and vendor selection following requirements.
  • Represent commercial priorities in digital and technology planning with field, marketing, Medical Affairs, Market Access, and commercial operations.
  • Translate commercial strategy into requirements for IT, vendors, and data teams, and communicate technical constraints and trade-offs to commercial leaders.
  • Partner with Marketing to build the marketing technology stack, performance marketing capability, and content infrastructure, and streamline medical, legal, and regulatory review so approved content reaches the field faster; identify AI opportunities for scaled content generation and adaptation and faster review workflows without lowering standards.
  • Partner with Sales and Field Force Excellence to equip the field with customer relationship management, call planning, territory management, and mobile tools; identify AI opportunities for next-best-action guidance, pre-call intelligence, and automation that returns selling time to representatives.
  • Partner with Medical Affairs to build capabilities for digital engagement, scientific exchange tools, congress engagement platforms, and key opinion leader mapping, while respecting its independent scientific strategy, content, and engagement priorities and the separation of promotional and non-promotional activities.
  • Partner with Market Access and Commercial Operations to establish contract management, chargeback and revenue management, and Sunshine Act compliance workflows; identify AI opportunities for anomaly detection, scenario modeling, and monitoring.
  • Serve as the primary liaison to the IT Commercial Lead, ensuring technology implementation aligns with commercial strategy.
  • Examine commercial launch capability areas—including marketing, field, Medical Affairs, market access, operations, and analytics—to identify where AI can improve existing work, enable new capabilities, or should not be used.
  • Evaluate whether AI can deliver more with less friction and greater speed before adding headcount, process, or traditional software.
  • Define and lead the AI capability roadmap for commercial and Medical Affairs organizations.
  • Deploy AI-powered strategic tools for the commercial leadership team, including virtual advisory simulations, pressure-testing frameworks, and intelligence briefing workflows.
  • Promote AI literacy and adoption across commercial functions, building fluency so field and marketing teams actively use AI tools.
  • Establish AI governance guardrails for commercial contexts with Legal and Compliance, defining permitted uses, conditions, and oversight.
  • Lead commercial evaluation of customer relationship management, marketing automation, data, and AI vendor options, distinguishing what to build, buy, or rent based on launch timelines, data readiness, and long-term scalability.
  • Maintain a composable, modular platform philosophy so each component can be replaced without requiring a full stack rebuild.
  • Ensure vendor contracts entered by the IT Commercial Lead receive commercial sign-off on scope, functionality, and success criteria before execution.
  • Define the commercial data strategy, including the data needed to compete at launch, when it must be procured, and how it will be activated and governed across customer relationship management, marketing, and analytics platforms.
  • Partner with the IT Commercial Lead to create data architecture for tracking and reporting commercial progress, ensuring performance metrics are captured, visible, and actionable across launch functions.
  • Partner with IT and Finance to ensure the master data management framework includes a commercial view so supply chain, quality, and commercial teams use a shared customer record.
  • Drive adoption of performance analytics and reporting tools across the commercial team, ensuring insights are accessible to field and marketing users.
Desired Qualifications
  • Experience launching U.S. vaccines and/or specialty biologics.

About the company

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Carlos, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • All three OPUS adult Phase 3 trials fully enrolled by August 2026, de-risking execution.
  • The FDA expanded VAX-31 Breakthrough Therapy designation in May 2025 to include pneumonia.
  • Thermo Fisher’s up-to-$1 billion agreement and Lonza manufacturing build support commercial readiness.

What critics are saying

  • VAX-31 OPUS-1 data shifted to October 2026, compressing launch timelines.
  • Q2 2026 burn reached $284.3 million, while cash funding depends on dilution.
  • Pfizer Prevnar 20 and Merck Capvaxive already control adult pneumococcal vaccination, threatening VAX-31 adoption.

What makes Vaxcyte unique

  • Vaxcyte’s XpressCF platform produced VAX-31, a 31-valent PCV, on September 10, 2026.
  • OPUS trials were finalized with FDA alignment for a planned BLA submission.
  • Thermo Fisher and Lonza manufacturing deals lock commercial capacity across U.S. and Europe.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-2%

2 year growth

0%
BBNS
Oct 7th, 2026
Biotech stocks to consider - october 5th.

Biotech stocks to consider - october 5th. Moderna, Vaxcyte, and Amgen are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies involved in developing and commercializing biotechnology products, such as pharmaceuticals, medical devices, diagnostics, and gene or cell therapies. For investors, these stocks can offer significant growth potential but often carry elevated risks due to clinical-trial outcomes, regulatory decisions, high research costs, and uncertain profitability. These companies had the highest dollar trading volume of any Biotech stocks within the last several days. Moderna (MRNA). Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. Discover more Shop Handbags View Collections Discover Luxury Vaxcyte (PCVX). Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. Amgen (AMGN). Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Yahoo Finance
Oct 6th, 2026
Vaxcyte's VAX-31 vaccine matches Pfizer's $6.49B Prevnar on all serotypes in Phase 3 trial

Vaxcyte announced its 31-valent pneumococcal vaccine, VAX-31, met all primary endpoints in a Phase 3 trial with 4,047 participants. The vaccine matched Pfizer's Prevnar 20 on all 20 shared serotypes and Merck's Capvaxive on 17 of 19 shared serotypes. Pfizer's Prevnar franchise generated $6.49 billion in 2025, representing roughly 10% of the company's $62.58 billion total revenue. The franchise grew just 1% last year, with Pfizer citing lower US market share. Merck's Capvaxive brought in $759 million in 2025, about 1% of its revenue. Pfizer trades at 9.87x forward earnings whilst Merck trades at 16.36x. Vaxcyte plans to file for approval in the first half of 2028. The company expects results from two additional trials in the first half of 2027.

Minyanville
Oct 5th, 2026
Vaxcyte launches dual $500M offerings of stock and convertible notes due 2032

Vaxcyte, a clinical-stage vaccine innovation company, has commenced underwritten public offerings of $500 million in common stock and pre-funded warrants, alongside $500 million in convertible senior notes due 2032. The company intends to grant underwriters a 30-day option to purchase an additional $75 million in each offering to cover over-allotments. The offerings are not contingent on each other and remain subject to market conditions. Jefferies, Leerink Partners, BofA Securities, and others are serving as joint book-running managers. Vaxcyte plans to use proceeds to fund clinical development of its VAX-31 adult and paediatric programmes, manufacturing scale-up, commercial investments for anticipated US launch, and research into early-stage pipeline vaccine candidates. The notes will accrue interest payable semi-annually and mature on 15 October 2032.

Yahoo Finance
Oct 5th, 2026
Vaxcyte soars 50% as pneumococcal vaccine beats Pfizer and Merck in late-stage trial

Vaxcyte's experimental pneumococcal vaccine VAX-31 met all main efficacy objectives in its first late-stage trial, sending shares soaring 50% and pushing the company's market value past $12 billion. The vaccine matched Pfizer's Prevnar 20 and Merck's Capvaxive in protecting against 28 bacterial strains and proved superior against three unique strains in adults aged 50 and older. VAX-31 was inferior on two strains using a stricter statistical threshold, though analysts called this a "near best-case scenario." Vaxcyte's shot targets the pneumococcal vaccine market worth $8 billion annually, dominated by Pfizer's franchise which earned over $6 billion last year. VAX-31 covers more than 30 strains, offering broader protection than existing vaccines. The company will report results from two additional late-stage trials next year before seeking regulatory approval.

STAT
Oct 5th, 2026
Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market.

Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market. Biotech company's pneumococcal vaccine hit primary endpoints in late-stage study. Oct. 5, 2026 General Assignment Reporter Vaxcyte said Monday that its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the California-based biotech to compete with Pfizer and Merck. Vaxcyte's shot, VAX-31, is designed to protect against 31 serotypes, or strains, of bacteria that can cause pneumococcal disease, including pneumonia, compared to 20 strains for Pfizer's Prevnar and 21 strains for Merck's Capvaxive. In the trial, just over 3,500 adults age 50 and older were randomized to receive VAX-31, Prevnar, or Capvaxive. Investigators then measured the strength of their antibody responses against different strains.